BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

SGHT

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

  • TearCare became the first and only MGD treatment indicated to improve meibomian gland function in patients with evaporative dry eye diseaseAug 19, 2026
  • Sight Sciences received FDA 510(k) clearance for the OMNI Ultra Surgical SystemAug 6, 2026
  • Sight Sciences announces publication of a systematic literature review and meta-analysis showing OMNI® Surgical System achieves clinically significant, long-term reductions in IOP and medication useSep 17, 2025
  • Sight Sciences announces recognition of the TearCare® system in TFOS DEWS III global dry eye guidelines published in AJOSep 3, 2025

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2026 Bio Pharma Stock. All rights reserved. Policy